Analyst firms · Morgan Stanley · NVO

Morgan Stanley NVO price target and rating history

Novo Nordisk A/S (NVO) · Health Care

Morgan Stanley rates Novo Nordisk A/S (NVO) Underweight with a $40 price target, as of its latest action on Sep 11, 2026. It has published 7 rating actions on NVO since April 2022, including 3 upgrades and 2 downgrades. Across 4 firms with a NVO price target in the last 12 months, the median target is $41.50. Morgan Stanley's $40 is 4% below that.

Current rating
Underweight
Price target
$40
Median target, all firms
$41.50
Actions on NVO
7

Morgan Stanley price target on NVO

$120$80$4020252026
Morgan Stanley price target on NVO, each point a stated target, January 2024 to September 2026.

Every Morgan Stanley rating on NVO

How other firms rate NVO

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
Morgan StanleyUnderweight$40Sep 11, 2026
Deutsche BankSellAug 27, 2026
BerenbergHoldAug 12, 2026
Wolfe ResearchPeer PerformMar 26, 2026
BernsteinUnderperform$175Mar 18, 2026
TD CowenHold$42Mar 10, 2026
Goldman SachsNeutral$41Mar 2, 2026
Kepler CheuvreuxHoldFeb 24, 2026
JefferiesHoldFeb 12, 2026
CitigroupNeutralJan 27, 2026
Argus ResearchHoldDec 8, 2025

Questions about Morgan Stanley and NVO

What is Morgan Stanley's price target for NVO?
Morgan Stanley's latest stated price target for Novo Nordisk A/S (NVO) is $40, from its action on Sep 11, 2026.
What is Morgan Stanley's rating on NVO?
Morgan Stanley rates NVO Underweight, a bearish rating, as of Sep 11, 2026.
When did Morgan Stanley last change its view on NVO?
On Sep 11, 2026, Morgan Stanley downgrades to Underweight from Equal-Weight, price target $40.
How does Morgan Stanley's NVO target compare with other analysts?
Across 4 firms with a NVO price target in the last 12 months, the median target is $41.50. Morgan Stanley's $40 is 4% below that.

More NVO rating histories

All Morgan Stanley ratingsNVO news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.